- Open Access
Binding mechanism of anti-cancer chemotherapeutic drug mitoxantrone to DNA characterized by magnetic tweezers
© The Author(s) 2018
- Received: 19 February 2018
- Accepted: 26 June 2018
- Published: 13 July 2018
Chemotherapeutic agents (anti-cancer drugs) are small cytostatic or cytotoxic molecules that often bind to double-stranded DNA (dsDNA) resulting in modifications of their structural and nanomechanical properties and thus interfering with the cell proliferation process.
We investigated the anthraquinone compound mitoxantrone that is used for treating certain cancer types like leukemia and lymphoma with magnetic tweezers as a single molecule nanosensor. In order to study the association of mitoxantrone with dsDNA, we conducted force-extension and mechanical overwinding experiments with a sensitivity of 10−14 N.
Using this method, we were able to estimate an equilibrium constant of association Ka ≈ 1 × 105 M−1 as well as a binding site size of n ≈ 2.5 base pairs for mitoxantrone. An unwinding angle of mitoxantrone-intercalation of ϑ ≈ 16° was determined.
Moreover, we observed a complex concentration-dependent bimodal binding behavior, where mitoxantrone associates to dsDNA as an intercalator and groove binder simultaneously at low concentrations and as a mere intercalator at high concentrations.
- Magnetic tweezers
- Groove binder
Regarding the high morbidity and mortality rate of cancer diseases in the recent decades, the development of cytostatic and cytotoxic chemotherapeutics is highly promoted. Several types of such anti-tumor agents, e.g. anthracycline, bind to DNA polymers in tumor/cancer cells and consequently result in an inhibition of cell growth (cytostatic/antiproliferative activity) or even necrosis (cytotoxic activity). Their heal efficacy depends strongly on the binding mode and the nanomechanism of the DNA-drug interaction. Therefore, a deep and thorough understanding of these biophysical characteristics of chemotherapeutics in the perspective of molecular recognition contributes significantly to the medical regulation and optimization of pharmaceutics.
Here, F, P, L(c), kBT and d represent the applied force, dsDNA persistence length, dsDNA contour length as functions of the drug concentration c, thermal energy and molecular extension of the dsDNA (end-to-end distance), respectively. Furthermore, we acquired reference “hat curves” via overwinding dsDNA to verify the nick-free structure of probed molecules.
At low MTX concentrations up to 3 µM, we discovered successive shifts of the force-extension curves indicating larger dsDNA contour lengths. Interestingly, at the same time the persistence length decreased from about 50 ± 2 to 42 ± 2 nm. Further increasing the drug concentration, merely an increment of the contour length was detected. At a drug concentration of 15 µM, we found a dsDNA-elongation of 27%. In previous work, we were able to categorize the binding mode of a dsDNA-binding agent by its influence on the nanomechanical properties of the host molecule, i.e. an intercalator elongates the dsDNA virtually without affecting the bending stiffness; in contrast, a groove binder only softens the dsDNA . That leads to the conclusion that MTX-dsDNA association exhibits a concentration-dependent bimodal binding mechanism. Primarily, MTX intercalates and groove-binds to dsDNA simultaneously, i.e. the planar anthraquinone ring interacts with the dsDNA base pairs in both intercalating and groove-like binding modes. Moreover, the aminoethylamino side chains bind electrostatically to the negatively charged phosphate backbones strengthening the MTX-dsDNA interaction. This matches with the results from the earlier reports [14–19, 22, 39–41]. Beyond the threshold concentration of 3 µM, the intercalation becomes dominant. Notably, in the case of bimodal binding, it is still not clear in which groove the electrostatic interaction occurs. Lown et al. and Wang et al. suggested that two aminoethylamino chains fit to the major groove by electrochemical experiments and a high-field 1H-NMR analysis, respectively [14, 18, 20]. In contrast, Mazerski et al. reported a minor-groove association of both side chains . Several other work found that the helically shaped chains of MTX can associate in both grooves. However, the interaction in the minor groove was found less favorable and sequence-selective [15, 16, 19].
Determination of binding mechanism
In addition, we approximated the fractional elongation data to the non-cooperative McGhee-von Hippel binding model (Fig. 2c) and obtained an elongation per intercalated drug molecule of ∆x = 0.37 ± 0.02 nm, corresponding to a rise of a B-DNA base pair (0.34 nm). The binding site size n was determined as n = 2.51 ± 0.11 bp, which is typical for a monointercalator and conforms to the “nearest neighbor exclusion principle” [42–44]. This matches very well with previous results [18, 21, 40] although earlier Kapuscinski et al. also reported a n-value of 5 bp for MTX . Analogously, we calculated an equilibrium constant of association of Ka = (0.98 ± 0.06) × 105 M−1, which is consistent with the results of Kapuscinski et al. of Ka = 2.5 × 105 M−1  but somewhat lower than published by other groups [15, 18, 22–25, 39]. However, since MTX apparently presents a more complex bimodal binding mode, the theoretical model might be of a somewhat limited applicability.
The overwinding experiments were recorded with added MTX concentrations up to 28 µM. The hat curve of bare dsDNA was taken as reference (black curve, Fig. 3a). By increasing the MTX concentration, an obvious shift of the hat curves to negative rotation numbers was observed, indicating a DNA unwinding and further supporting the intercalative binding mode of MTX . In addition, a height increment of the hat curves implies an intercalation induced dsDNA elongation that is fully consistent with our extension experiments .
Moreover, we evaluated and plotted the change in the rotation number ΔR and the elongation of the dsDNA contour length ΔL (Fig. 3b). The linear approximation of the data gave us a slope of 0.121 ± 0.002 turns/nm.
In summary, we investigated the nanomechanical binding mechanism of MTX to dsDNA at room temperature in PBS buffer by employing a MT single molecule nanosensor. As a conventional mono-intercalator, MTX displayed a fast equilibrium assembly compared with bis-intercalators and threading intercalators [53–58]. By means of extending and overwinding individual DNA molecules, we observed an elongation, softening and untwisting of the DNA double helix upon MTX binding in a concentration dependent manner. Based on earlier findings , we identified a bimodal association mode, i.e. MTX exhibits simultaneously an intercalative and groove-binding behavior. In addition, we determined a threshold concentration of 3 µM at which the primary bimodal association declines and mere intercalation becomes dominant. Furthermore, we estimated a binding site size of n ≈ 2.5 bp, which corresponds to the results of previous reports (n = 2.6–3.0 bp) [18, 21, 40]. An elongation of Δx ≈ 0.37 nm induced by each drug molecule was estimated, which is typical for a mono-intercalator, since the bond between the drug molecule and DNA base pairs is stabilized through π-stacking. Moreover, we found that each intercalated MTX molecule unwinds the native DNA helix with an angle θ of about 16°, compensating the elongation-induced tension. Finally, the equilibrium constant of association of MTX-dsDNA interaction was determined to be about Ka ≈ 1 × 105 M−1, which is significantly lower than in previous reports [15, 18, 22–25, 39]. However, other anthraquinone derivates like DRAQ5 were found to occupy a similar binding affinity to DNA [33, 59–63]. The results of this work help to further characterize and quantify the biophysical binding mode of mitoxantrone to dsDNA and in turn support the medical regulation processes.
DA, KT, MR and YW designed the study. KT and YW contributed substantially to the sample preparation. DK performed all measurements and analyzed the data. DK, YW and DA wrote the manuscript. All authors read and approved the final manuscript.
We gratefully acknowledge Helene Schellenberg and Christoph Pelargus for the technical supports.
The authors declare that they have no competing interests.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Consent for publication
Ethics approval and consent to participate
This work is financially supported by the Project AN 370/8-1 from the Deutsche Forschungsgemeinschaft as well as by the Strategy Funds of Bielefeld University.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/4212. PubChem Compound Database. Accessed 2018 Jan 29.
- Zee-Cheng RKY, Cheng CC. Antineoplastic agents. Structure–activity relationship study of bis(substituted aminoalkylamino)anthraquinones. J Med Chem. 1978;21:291–4.View ArticleGoogle Scholar
- Murdock KC, Child RG, Fabio PF, Angier RB, Wallace RE, Durr FE, et al. Antitumor Agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones. J Med Chem. 1979;22:1024–30.View ArticleGoogle Scholar
- Wu C-C, Li Y-C, Wang Y-R, Li T-K, Chan N-L. On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs. Nucleic Acids Res. 2013;41:10630–40.View ArticleGoogle Scholar
- Holmes FA, Yap H-Y, Esparza L, Buzdar AU, Hortobagyi GN, Blumenschein GR. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. Semin Oncol. 1984;11:28–31.Google Scholar
- Smith PJ, Morgan SA, Fox ME, Watson JV. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochem Pharmacol. 1990;40:2069–78.View ArticleGoogle Scholar
- Thomas X, Archimbaud E. Mitoxantrone in the treatment of acute myelogenous leukemia: a review. Hematol Cell Ther. 1997;39:163–74.View ArticleGoogle Scholar
- Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs. 2004;18:379–96.View ArticleGoogle Scholar
- Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010;376:2009–17.View ArticleGoogle Scholar
- Posner LE, Dukart G, Goldberg J, Bernstein T, Cartwright K. Mitoxantrone: an overview of safety and toxicity. Invest New Drugs. 1985;3:123–32.View ArticleGoogle Scholar
- White RJ, Durr FE. Development of mitoxantrone. Invest New Drugs. 1985;3:85–93.View ArticleGoogle Scholar
- Alderton PM, Green MD. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res. 1992;52:194–201.Google Scholar
- Koutinos G, Stathopoulos GP, Dontas I, Perrea-Kotsarelis D, Couris E, Karayannacos PE, et al. The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: an experimental study. Anticancer Res. 2002;22:815–20.Google Scholar
- Lown JW, Hanstock CC. High Field 1H-NMR analysis of the 1:1 intercalation complex of the antitumor agent mitoxantrone and the DNA duplex [d(CpGpCpG)]2. J Biomol Struct Dyn. 1985;2:1097–106.View ArticleGoogle Scholar
- Lown JW, Morgan AR, Yen SF, Wang YH, Wilson WD. Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids. Biochemistry. 1985;24:4028–35.View ArticleGoogle Scholar
- Chen K-X. A theoretical investigation on the sequence selective binding of mitoxantrone to double-stranded tetranucleotides. Nucleic Acids Res. 1986;14:3799–812.View ArticleGoogle Scholar
- Mazerski J, Martelli S, Borowski E. The geometry of intercalation complex of antitumor mitoxantrone and ametantrone with DNA: molecular dynamics simulations. Acta Biochim Pol. 1998;45:1–11.Google Scholar
- Wang S, Peng T, Yang CF. Electrochemical determination of interaction parameters for DNA and mitoxantrone in an irreversible redox process. Biophys Chem. 2003;104:239–48.View ArticleGoogle Scholar
- Parker BS, Buley T, Evison BJ, Cutts SM, Neumann GM, Iskander MN, et al. A molecular understanding of mitoxantrone-DNA adduct formation. J Biol Chem. 2004;279:18814–23.View ArticleGoogle Scholar
- Varadwaj P, Misra K, Sharma A, Kumar R. Mitoxantrone: an agent with promises for anticancer therapies. Electron J Biol. 2010;6:36–42.Google Scholar
- Kapuscinski J, Darzynkiewicz Z. Interactions of antitumor agents Ametantrone and Mitoxantrone (Novatrone) with double-stranded DNA. Biochem Pharmacol. 1985;34:4203–13.View ArticleGoogle Scholar
- Rosenberg LS, Carvlin MJ, Krugh TR. The antitumor agent mitoxantrone binds cooperatively to DNA: evidence for heterogeneity in DNA conformation. Biochemistry. 1986;25:1002–8.View ArticleGoogle Scholar
- Zagotto G, Sissi C, Palumbo G. Aminoacyl-analogues of mitoxantrone as novel DNA-damaging cytotoxic agents. Arkivoc. 2004;5:204–18.Google Scholar
- Hajihassan Z, Rabbani-Chadegani A. Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins. J Biomed Sci. 2009;16:31.View ArticleGoogle Scholar
- Bhattacharyya J, Basu A, Suresh Kumar G. Intercalative interaction of the anticancer drug mitoxantrone with double stranded DNA: a calorimetric characterization of the energetics. J Chem Thermodyn. 2014;75:45–51.View ArticleGoogle Scholar
- Strick TR, Allemand JF, Bensimon D, Bensimon A, Croquette V. The elasticity of a single supercoiled DNA molecule. Science. 1996;271:1835–7.View ArticleGoogle Scholar
- Strick TR, Allemand JF, Bensimon D, Croquette V. Behavior of supercoiled DNA. Biophys J. 1998;74:2016–28.View ArticleGoogle Scholar
- Vilfan ID, Lipfert J, Koster DA, Lemay SG, Dekker NH. Magnetic tweezers for single-molecule experiments. In: van Hinterdorfer O, editor. Handbook single-molecule biophys. New York: Springer; 2009. p. 371–96.View ArticleGoogle Scholar
- Jany T, Moreth A, Gruschka C, Sischka A, Spiering A, Dieding M, et al. Rational design of a cytotoxic dinuclear Cu2 complex that binds by molecular recognition at two neighboring phosphates of the Dna backbone. Inorg Chem. 2015;54:2679–90.View ArticleGoogle Scholar
- Glaser T, von Mollard GF, Anselmetti D. Rational design of dinuclear complexes binding at two neighboring phosphate esters of DNA. Inorganica Chim Acta. 2016;452:62–72.View ArticleGoogle Scholar
- Wang Y, Schellenberg H, Walhorn V, Toensing K, Anselmetti D. Binding mechanism of PicoGreen to DNA characterized by magnetic tweezers and fluorescence spectroscopy. Eur Biophys J. 2017;46:561–6.View ArticleGoogle Scholar
- Cheng W. Protocol to generate half Lambda DNA for optical/magnetic tweezer. 2006. p. 6–9. http://tweezerslab.unipr.it/cgi-bin/mt/documents.pl/Show?_id=ab03&sort=DEFAULT&search=&hits=23. Accessed 2008 Sept 5.
- Wang Y, Sischka A, Walhorn V, Tönsing K, Anselmetti D. Nanomechanics of fluorescent DNA Dyes on DNA investigated by magnetic tweezers. Biophys J. 2016;111:1604–11.View ArticleGoogle Scholar
- Bustamante C, Marko JF, Siggia ED, Smith S. Entropic elasticity of X-phage DNA. Science. 1994;265:1599–600.View ArticleGoogle Scholar
- Bouchiat C, Wang MD, Allemand JF, Strick T, Block SM, Croquette V. Estimating the persistence length of a worm-like chain molecule from force-extension measurements. Biophys J. 1999;76:409–13.View ArticleGoogle Scholar
- McGhee JD, von Hippel PH. Theoretical aspects of DNA-protein interactions: co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice. J Mol Biol. 1974;86:469–89.View ArticleGoogle Scholar
- Vladescu ID, McCauley MJ, Nuñez ME, Rouzina I, Williams MC. Quantifying force-dependent and zero-force DNA intercalation by single-molecule stretching. Nat Methods. 2007;4:517–22.View ArticleGoogle Scholar
- Kleimann C, Sischka A, Spiering A, Tönsing K, Sewald N, Diederichsen U, et al. Binding kinetics of bisintercalator triostin a with optical tweezers force mechanics. Biophys J. 2009;97:2780–4.View ArticleGoogle Scholar
- Kapuscinski J, Darzynkiewicz Z. Interactions of a new antitumor agent, 1,4-dihydroxy-5, 8-bis-ethyl] amino]-9, 10-anthracenedione, with nucleic acids. Biochem Pharmacol. 1981;30:231–40.View ArticleGoogle Scholar
- Foye WO, Vajragupta O, Sengupta SK. DNA-binding specificity and RNA polymerase inhibitory activity of Bis(aminoalky1)anthraquinones and Bis(methy1thio)vinylquinolinium Iodides. J Pharm Sci. 1982;71:253–7.View ArticleGoogle Scholar
- Tang L. Study on the interaction of anticancer drug mitoxantrone with DNA by fluorescence and Raman spectroscopies. Chinese Opt Lett. 2006;4:101–4.Google Scholar
- Crothers DM. Calculation of binding isotherms for heterogeneous polymers. Biopolymers. 1968;6:575–84.View ArticleGoogle Scholar
- Müller W, Crothers DM. Studies of the binding of actinomycin and related compounds to DNA. J Mol Biol. 1968;35:251–90.View ArticleGoogle Scholar
- Williams LD, Eglifgb M, Gao Q, Ricfgh A. DNA intercalation: helix unwinding and neighbor-exclusion. In: Sarma RH, Sarma MH, editors. Structure functional nucleic acids. Schenectady: Adenine Press; 1992.Google Scholar
- Strick TR, Dessinges M-N, Charvin G, Dekker NH, Allemand J-F, Bensimon D, et al. Stretching of macromolecules and proteins. Reports Prog Phys. 2003;66:1–45.View ArticleGoogle Scholar
- Salerno D, Brogioli D, Cassina V, Turchi D, Beretta GL, Seruggia D, et al. Magnetic tweezers measurements of the nanomechanical properties of DNA in the presence of drugs. Nucleic Acids Res. 2010;38:7089–99.View ArticleGoogle Scholar
- Rutkauskas M, Krivoy A, Szczelkun MD, Rouillon C, Seidel R. Single-molecule insight into target recognition by CRISPR–Cas complexes. 1st ed. Schenectady: Academic Press; 2017. p. 239–73.Google Scholar
- Wang Y, van Merwyk L, Toensing K, Walhorn V, Anselmetti D, Fernàndez-Busquets X. Biophysical characterization of the association of histones with single-stranded DNA. Biochim Biophys Acta Gen Subj. 2017;1861:2739–49.View ArticleGoogle Scholar
- Guenther K, Mertig M, Seidel R. Mechanical and structural properties of YOYO-1 complexed DNA. Nucleic Acids Res. 2010;38:6526–32.View ArticleGoogle Scholar
- Lipfert J, Klijnhout S, Dekker NH. Torsional sensing of small-molecule binding using magnetic tweezers. Nucleic Acids Res. 2010;38:7122–32.View ArticleGoogle Scholar
- Szczelkun MD, Tikhomirova MS, Sinkunas T, Gasiunas G, Karvelis T, Pschera P, et al. Direct observation of R-loop formation by single RNA-guided Cas9 and Cascade effector complexes. Proc Natl Acad Sci. 2014;111:9798–803.View ArticleGoogle Scholar
- Rutkauskas M, Sinkunas T, Songailiene I, Tikhomirova MS, Siksnys V, Seidel R. Directional R-loop formation by the CRISPR–cas surveillance complex cascade provides efficient off-target site rejection. Cell Rep. 2015;10:1534–43.View ArticleGoogle Scholar
- Krishnamoorthy CR, Yen SF, Smith JC, Lown JW, Wilson WD. Stopped-flow kinetic analysis of the interaction of anthraquinone anticancer drugs with calf thymus DNA, poly[d(G-C)].cntdot.poly[d(G-C)], and poly[d(A-T)].cntdot.poly[d(A-T)]. Biochemistry. 1986;25:5933–40.View ArticleGoogle Scholar
- Hayashi M, Harada Y. Direct observation of the reversible unwinding of a single DNA molecule caused by the intercalation of ethidium bromide. Nucleic Acids Res. 2007;35:e125.View ArticleGoogle Scholar
- Murade CU, Subramaniam V, Otto C, Bennink ML. Interaction of oxazole yellow dyes with DNA studied with hybrid optical tweezers and fluorescence microscopy. Biophys J Biophys Soc. 2009;97:835–43.View ArticleGoogle Scholar
- Almaqwashi AA, Paramanathan T, Lincoln P, Rouzina I, Westerlund F, Williams MC. Strong DNA deformation required for extremely slow DNA threading intercalation by a binuclear ruthenium complex. Nucleic Acids Res. 2014;42:11634–41.View ArticleGoogle Scholar
- Biebricher AS, Heller I, Roijmans RFH, Hoekstra TP, Peterman EJG, Wuite GJL. The impact of DNA intercalators on DNA and DNA-processing enzymes elucidated through force-dependent binding kinetics. Nat Commun. 2015;6:7304–15.View ArticleGoogle Scholar
- Almaqwashi AA, Paramanathan T, Rouzina I, Williams MC. Mechanisms of small molecule—DNA interactions probed by single-molecule force spectroscopy. Nucleic Acids Res. 2016;44:3971–88.View ArticleGoogle Scholar
- Costantino L, Guarino G, Ortona O, Vitagllano V. Acridine orange association equilibrium in aqueous solution. J Chem Eng Data. 1984;29:62–6.View ArticleGoogle Scholar
- Roche CJ, Berkowitz D, Sulikowski GA, Danishefsky SJ, Crothers DM. Binding affinity and site selectivity of daunomycin analogues. Biochemistry. 1994;33:936–42.View ArticleGoogle Scholar
- Breslin DT, Yu C, Ly D, Schuster GB. Structural modification changes the DNA binding mode of cation- substituted anthraquinone photonucleases: association by intercalation or minor groove binding determines the DNA cleavage efficiency. Biochemistry. 1997;36:10463–73.View ArticleGoogle Scholar
- McKnight RE, Zhang J, Dixon DW. Binding of a homologous series of anthraquinones to DNA. Bioorganic Med. Chem. Lett. 2004;14:401–4.View ArticleGoogle Scholar
- Wang Y, Schellenberg H, Walhorn V, Toensing K, Anselmetti D. Binding mechanism of fluorescent dyes to DNA characterized by magnetic tweezers. Mater Today Proc. 2017;4:218–25.View ArticleGoogle Scholar